Compare PubMatic Inc (PUBM) vs Regeneron Pharmaceuticals Inc (REGN) Price & Performance

PubMatic (PUBM) trades at $16.29, down 1.27% on the day, with a bullish technical signal driven by moving averages and recent support above the 20-day average. The company reported Q2 2026 revenue growth of 11% year-over-year and an EPS beat, though net income margins remain negative. Positive sentiment is fueled by AI-driven ad tech adoption and strategic hires, such as the new Global Chief Revenue Officer.

Outlook: Strong analyst consensus (64.7% buy ratings) and a $20.83 price target suggest upside potential from AI product momentum and cost controls. Risks include persistent profitability challenges and CFO transition uncertainty. The stock offers growth exposure but requires monitoring of margin improvement.

Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.

Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.